微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Midostaurin
Midostaurin

肿瘤

关键词肿瘤 药物 白血病

词汇介绍

拓展阅读

解析

Midostaurin 

释    义   n. 米哚妥林

例    句   The natural history of FLT3-mutated AML is changing after the approval of midostaurin for frontline therapy and gilteritinib for relapsed or refractory patients. 在米哚妥林和吉特替尼被批准用于一线治疗和复发或难治性患者后,FLT3突变的AML的自然史正在改变。

概述

2017年4月28日,美国食品药品管理局(FDA)批准了米哚妥林上市,用于治疗FLT3+的急性髓系白血病(AML)。米哚妥林是由瑞士诺华生产的,是25年来AML首款新药,也是第一款与化疗联用治疗AML的靶向药物。米哚妥林是多种激酶抑制剂,能抑制包括FLT3、PKC、C-FOS、MAPK、PDGFR、CDK1、KIT、VEGF等多种激酶活性。   国际多中心FLT3+ AML 3期临床试验中,研究人员检测了3277例AML,招募了其中符合要求的717例FLT3+患者,并将他们随机

Sorafenib Plus Intensive Chemotherapy Improves Survival in Patients With Newly Diagnosed, FLT3-Internal Tandem Duplication Mutation–Positive Acute Myeloid Leukemia复制标题

索拉非尼加强化化疗可改善新诊断的FLT3-Internal串联重复突变阳性急性髓系白血病患者的生存率

发表时间:2019-11-01

影响因子:6.1

作者: Koji Sasaki

期刊:Cancer

BACKGROUND: The addition of midostaurin to induction chemotherapy improves survival in younger patients with newly diagnosed, FLT3-mutated acute myeloid leukemia (AML). Sorafenib is a potent multikinase inhibitor with efficacy when given as monotherapy. The authors investigated whether the addition of sorafenib to intensive induction chemotherapy improves outcomes in patients with FLT3-internal tandem duplication (ITD)-mutated AML. METHODS: In total, 183 patients who were newly diagnosed with FLT3-ITD-mutated AML between February 2001 and December 2017 were identified. Of these, 79 patients (43%) underwent intensive chemotherapy with the addition of sorafenib, and 104 (57%) received intensive chemotherapy alone. Propensity score matching identified 42 patients in each cohort.

译文

背景:新诊断的FLT3突变的急性髓系白血病(AML)患者,在诱导化疗中加入米多糖可提高其生存率。索拉非尼是一种有效的多激酶抑制剂,单药治疗有效。作者研究了在强化诱导化疗中加入索拉非尼是否能改善FLT3内串联重复(ITD)突变AML患者的预后。方法:对2001年2月至2017年12月新诊断的183例FLT3-ITD突变AML患者进行分析。其中79例(43%)接受强化化疗并加用索拉非尼,104例(57%)单独接受强化化疗倾向性评分匹配在每个队列中确定了42名患者。